Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00352261 · ClinicalTrials.gov registry record · Phase 4
An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients
A Phase 4 study of Barrett's Esophagus, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
- 12
- Study locations
NCT00352261: Completed Phase 4 study of Barrett's Esophagus, sponsored by AstraZeneca.
NCT00352261 is a Phase 4 study of Barrett's Esophagus that has completed, run by AstraZeneca. The registered enrollment target is 80 participants, below the 521-participant average among 22 other Barrett's Esophagus trials with a reported enrollment target (85% lower). The trial reports 12 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00352261, a Phase 4 study of Barrett's Esophagus, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of the study is to compare the treatment of esomeprazole 40 mg once daily and lansoprazole 30 mg once daily in controlling intragastric pH in Barrett's Esophagus patients
Conditions Studied
Interventions
- DRUG Esomeprazole
- DRUG Lansoprazole
Study Locations (12)
Arizona
- Research Site - Phoenix
- Research Site - Tucson
Missouri
- Research Site - Kansas City
- Research SIte - Springfield
Illinois
- Research Site - North Chicago
Minnesota
- Research Site - Rochester
Montana
- Research Site - Butte
Ohio
- Research Site - Cleveland
Pennsylvania
- Research Site - Philadelphia
Tennessee
- Research Site - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2006-01 |
| Est. Completion | 2007-04 |
| Phase | Phase 4 |
What the finished NCT00352261 record still lists
NCT00352261 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 521-participant average among 22 other Barrett's Esophagus trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Barrett's Esophagus appearing as the primary indexed condition, and to 2 interventions - of which Esomeprazole is the first listed.
NCT00352261 lists 12 locations in 10 states (Arizona, Missouri, Illinois).
Frequently Asked Questions
What is clinical trial NCT00352261 about?
NCT00352261 is a clinical study titled "An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients". The purpose of the study is to compare the treatment of esomeprazole 40 mg once daily and lansoprazole 30 mg once daily in controlling intragastric pH in Barrett's Esophagus patients
What is the current status of trial NCT00352261?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2006-01. Estimated completion is 2007-04.
What conditions does trial NCT00352261 study?
This clinical trial studies the following conditions: Barrett's Esophagus.
What interventions are being tested in trial NCT00352261?
The interventions under investigation include: Esomeprazole (DRUG), Lansoprazole (DRUG).
Who is sponsoring clinical trial NCT00352261?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00352261 being conducted?
This trial has 12 study locations across Arizona, Illinois, Minnesota, Missouri, Montana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Barrett's Esophagus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00352261's enrollment target sits among peer trials
80 12th of 22 higher than 11 of 22 other Barrett's Esophagus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Barrett's Esophagus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of CryoSpray Ablation(TM)to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus.
COMPLETED · Phase 4
-
Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids
COMPLETED · Phase 4
-
Pilot Study for TCE Imaging of the Esophagus Using an OFDI Capsule With a Compact Imaging System
RECRUITING · NA
-
Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry
RECRUITING
-
Barrett's Esophagus Related Neoplasia (BERN) Project
RECRUITING
-
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia